Jun Xie to Transgenes
This is a "connection" page, showing publications Jun Xie has written about Transgenes.
Connection Strength
0.604
-
Chen X, Xie Q, Nath SJ, Tang M, Ma H, G?nes Y?, Sharma T, Liu H, Cui M, Du A, Lu M, Liu SY, Wassamon B, Xu M, Wu JY, Su Q, Fitzgibbons TP, Liu J, Wan F, Kumanan V, He R, Ma Y, Yang J, Gray-Edwards HL, Gallagher TL, Tai PWL, Gao G, Xie J. Long-term comparative analysis of AAV9-mediated gene replacement therapies for spinal muscular atrophy in mice. Nat Commun. 2026 May 23; 17(1).
Score: 0.225
-
Xie Q, Chen X, Ma H, Zhu Y, Ma Y, Jalinous L, Cox GF, Weaver F, Yang J, Kennedy Z, Gruntman A, Du A, Su Q, He R, Tai PW, Gao G, Xie J. Improved gene therapy for spinal muscular atrophy in mice using codon-optimized hSMN1 transgene and hSMN1 gene-derived promotor. EMBO Mol Med. 2024 04; 16(4):945-965.
Score: 0.193
-
Xu M, Li J, Xie J, He R, Su Q, Gao G, Tai PWL. High-Throughput Quantification of In Vivo Adeno-Associated Virus Transduction with Barcoded Non-Coding RNAs. Hum Gene Ther. 2019 08; 30(8):946-956.
Score: 0.139
-
Davis-Gardner ME, Weber JA, Xie J, Pekrun K, Alexander EA, Weisgrau KL, Furlott JR, Rakasz EG, Kay MA, Gao G, Farzan M, Gardner MR. A strategy for high antibody expression with low anti-drug antibodies using AAV9 vectors. Front Immunol. 2023; 14:1105617.
Score: 0.046